Stay updated with breaking news from Denis Bedoret. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Imcyse SA / Key word(s): Study Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis 13.09.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Imcyse Announces Complet...
EQS-News: Imcyse SA / Key word(s): Miscellaneous Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis 22.06.2023 / 10:30 CET/CEST The issuer is solely responsible for the content of this announcement. Imcy...
Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis
Exceeded target enrollment with 110 patients randomized across 28 clinical sites in Europe, the United States and AustraliaEfficacy proof-of-concept data from IMPACT is expected in Q1 2024. Following
EQS-News: Imcyse SA / Key word(s): Study Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes 01.03.2023 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Imcyse Announces Completion of Enrollment in Phase 2 IMPA...